SCHEDULE: State Street Discloses 4.7% Stake in Cytokinetics

State Street Corporation has filed a Schedule 13G, reporting a 4.7% beneficial ownership stake in Cytokinetics Inc. common stock as of September 30, 2025.

Summary

• State Street Corporation, a Massachusetts-based holding company, has reported beneficial ownership of 5,617,334 shares of Cytokinetics Inc. common stock.
• This ownership represents 4.7% of the total class of Cytokinetics Inc. common stock.
• The filing indicates that State Street Corporation holds shared voting power over 5,262,728 shares and shared dispositive power over 5,617,334 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Cytokinetics Inc.
• The event date requiring this filing was September 30, 2025, with the statement signed on November 7, 2025.
• Subsidiaries involved in the acquisition include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of institutional ownership, providing factual information without indicating positive or negative sentiment regarding the issuer's performance or future prospects.

Positives

• The disclosure of a significant institutional stake by State Street Corporation, a major financial institution, may signal a degree of confidence in Cytokinetics Inc. as a passive investment.

Negatives

• The reported stake of 4.7% is below the 5% threshold that typically triggers initial Schedule 13G filings for passive investors, which could imply a reduction in holdings if State Street previously held more than 5%.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Cytokinetics Inc.'s future performance or State Street Corporation's investment strategy beyond the current reported holdings.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Institutional investors like State Street Corporation routinely hold passive stakes in publicly traded companies as part of their asset management and index-tracking activities. This filing reflects State Street's current passive investment position in Cytokinetics Inc., aligning with broader trends of institutional capital allocation in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders of Cytokinetics Inc. will note the significant, albeit passive, institutional ownership by State Street Corporation, which can be interpreted as a baseline level of institutional interest in the company.

Key Dates

Keywords

Cytokinetics Inc., State Street Corporation, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Equity Holdings, Financial Disclosure